Patented Immunotherapy for Cancer, Achieving up to 10 Billion Activated Cells

Filter by Sector: Healthcare, Biotechnology, Advanced Medical Treatment Filter by Country: Japan, Vietnam

I. The Challenge & Breakthrough Solution
Over 53% of cancer patients face severe side effects from conventional therapies, leading

to decreased Quality of Life (QOL).

BAK Immuno-Cell Therapy is the Fourth Pillar of Cancer Treatment. This patented technology uses the patient’s own lymphocytes (immune cells) to attack malignant cells with minimal side effects.

Mechanism: The process cultivates a potent mixture of immune cells (NK Cells, T Cells, Killer T Cells), ensuring a multi-directional attack that maintains effectiveness even against advanced tumors

II. Core Benefits & Clinical Results

The BAK technology, patented for its highly activated lymphocyte composition, provides dual benefits for treatment and prevention:

Scope of Application: Adjuvant therapy for Stages I-IV Cancer, Post-operative recurrence prevention, and Preventive Medicine.

III. Exclusive Collaboration Opportunities
BBT Holdings seeks exclusive strategic partners in BRICS+ to deploy this technology:

1. Exclusive Licensing & Technology Transfer: Grant the right to implement and market BAK Therapy (1 country/1 partner).

2. Cell Processing Facility (CPF) Setup: Full support for establishing, operating, and managing a local CPF compliant with Japanese standards.

3. Patient Referral System: Establish an international patient referral system (Inbound/Outbound).

Expansion Goal: Establish exclusive alliances with top healthcare groups to localize Japan’s advanced cell-processing technology.